Influence of Polymorphisms in the ATP6V1 Gene of the V-ATPase on the Development of Incomplete Distal Renal Tubular Acidosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01690039|
Recruitment Status : Recruiting
First Posted : September 21, 2012
Last Update Posted : November 28, 2016
- To compare the performance of the two currently employed urinary acidifications tests in stone formers, the furosemide/fludrocortisone and ammonium chloride loading test.
- To study the impact of polymorphisms in the genes ATP6V1B1, ATP6V0A4 and SLC4A1 on urinary acidification in stone formers.
|Condition or disease||Intervention/treatment|
|Acidosis, Renal Tubular Nephrolithiasis Vacuolar Proton-Translocating ATPases||Drug: Furosemide-Fludrocortisone-Test (test for urinary acidification)|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Comparison of Furosemide/Fludrocortisone With Ammonium Chloride Loading Test in the Diagnosis of Incomplete dRTA in Kidney Stone Formers|
|Study Start Date :||September 2012|
|Estimated Primary Completion Date :||September 2017|
|Estimated Study Completion Date :||September 2017|
All study participants
Furosemide-Fludrocortisone-Test and Ammonium chloride-Loading Test will be performed in renal stone patients.
Drug: Furosemide-Fludrocortisone-Test (test for urinary acidification)
The presence of a lack of urinary acidification will be assessed by an appropriate test in all patients.
Other Name: Application of Furosemide (Lasix® ) and Fludrocortisone (Florinef®)
- Capability of urinary acidification [ Time Frame: Five to six hours ]
- Polymorphisms in the ATP6V1 gene [ Time Frame: 12 months ]
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01690039
|Contact: Daniel Fuster, Attending physician Nephrology||++41 (0)31 631 37 email@example.com|
|Contact: Nasser Dhayat, Resident Nephrology||++41 (0)31 632 31 firstname.lastname@example.org|
|Department of Nephrology and Hypertension, Bern University Hospital||Recruiting|
|Bern, Switzerland, 3010|
|Principal Investigator: Fuster Daniel, Attending physician Nephrology|
|Sub-Investigator: Nasser Dhayat, Resident Nephrology|
|Principal Investigator:||Daniel Fuster, Attending physician Nephrology||Department of Nephrology and Hypertension, Bern University Hospital|